Abstract
To the Editor: Dermatologic toxicities are often the earliest-presenting and highest-incidence adverse events (AEs) due to targeted anticancer therapies and immunotherapies.1 Nail unit toxicities due to immunotherapy are caused by nonspecific immune activation. Targeted therapies, particularly mitogen-activated protein kinase pathway inhibitors, lead to epidermal thinning of the nailfolds and periungual tissue, increasing susceptibility to trauma and penetration by nail plate fragments. Paronychia may develop and evolve into onychocryptosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
